http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Alireza Saadat (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Effects of Spinal-Z in Patients with Gastroesophageal Cancer
Yunes Panahi,Alireza Saadat,Maghsoud Seifi,Mahdi Rajaee,Alexandra E. Butler,Amirhossein Sahebkar 대한약침학회 2018 Journal of pharmacopuncture Vol.21 No.1
Objective: The purpose of this study was to investigate the efficacy and safety of spinal-Z, derived from Peganum harmala seeds and Dracocephalum Kotschyi Boiss leaves, in patients with esophageal and stomach adenocarcinoma, and squamous cell carcinoma of the esophagus. Methods: Sixty-one patients with malignancies of the upper gastrointestinal tract were randomly assigned to one of two groups (treatment or control) in a double-blind fashion. Six capsules of Spinal-Z were prescribed to the patients with the regimen of 600 mg/m2/ day, and placebo to the control group, for six months. Results: There were no significant differences between the two groups with regard to age, sex, duration of cancer, type of cancer and family history of cancer. There were significant differences in abdominal pain, heartburn, constipation and vomiting between the two groups, following spinal-Z therapy. Evaluation of drug side effects showed no difference in cough or other respiratory symptoms, itching, headache or dizziness between the two groups, both before and after treatment. Conclusion: This study indicates that Spinal-Z is safe and efficacious in the management of patients with upper gastrointestinal tract cancers.
-
Effects of Spinal-Z in Patients with Gastroesophageal Cancer
Panahi, Yunes,Saadat, Alireza,Seifi, Maghsoud,Rajaee, Mahdi,Butler, Alexandra E.,Sahebkar, Amirhossein KOREAN PHARMACOPUNCTURE INSTITUTE 2018 Journal of pharmacopuncture Vol.21 No.1
Objective: The purpose of this study was to investigate the efficacy and safety of spinal-Z, derived from Peganum harmala seeds and Dracocephalum Kotschyi Boiss leaves, in patients with esophageal and stomach adenocarcinoma, and squamous cell carcinoma of the esophagus. Methods: Sixty-one patients with malignancies of the upper gastrointestinal tract were randomly assigned to one of two groups (treatment or control) in a double-blind fashion. Six capsules of Spinal-Z were prescribed to the patients with the regimen of 600 mg/m2/day, and placebo to the control group, for six months. Results: There were no significant differences between the two groups with regard to age, sex, duration of cancer, type of cancer and family history of cancer. There were significant differences in abdominal pain, heartburn, constipation and vomiting between the two groups, following spinal-Z therapy. Evaluation of drug side effects showed no difference in cough or other respiratory symptoms, itching, headache or dizziness between the two groups, both before and after treatment. Conclusion: This study indicates that Spinal-Z is safe and efficacious in the management of patients with upper gastrointestinal tract cancers.
-
Fereidoun Azizi,Navid Saadat,Mir Alireza Takyar,Hengameh Abdi,Ladan Mehran,Atieh Amouzegar 대한내분비학회 2022 Endocrinology and metabolism Vol.37 No.6
Background: This study compared the degree of sustained control of hyperthyroidism in patients with toxic multinodular goiter(TMNG) treated with long-term methimazole (LT-MMI) or radioactive iodine (RAI). Methods: In this clinical trial, 130 untreated patients with TMNG were randomized to either LT-MMI or RAI treatment. Bothgroups were followed for 108 to 148 months, with median follow-up durations of 120 and 132 months in the LT-MMI and RAIgroups, respectively. Both groups of patients were followed every 1 to 3 months in the first year and every 6 months thereafter. Results: After excluding patients in whom the treatment modality was changed and those who were lost to follow-up, 53 patients inthe LT-MMI group and 54 in the RAI group completed the study. At the end of the study period, 50 (96%) and 25 (46%) patientswere euthyroid, and two (4%) and 25 (46%) were hypothyroid in LT-MMI and RAI groups, respectively. In the RAI group, four(8%) patients had subclinical hyperthyroidism. The mean time to euthyroidism was 4.3±1.3 months in LT-MMI patients and 16.3±15.0 months in RAI recipients (P<0.001). Patients treated with LT-MMI spent 95.8%±5.9% of the 12-year study period in a euthyroid state, whereas this proportion was 72.4%±14.8% in the RAI-treated patients (P<0.001). No major treatment-related adverseevents were observed in either group. Conclusion: In patients with TMNG, LT-MMI therapy is superior to RAI treatment, as shown by the earlier achievement of euthyroidism and the longer duration of sustained normal serum thyrotropin.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
